DOCSLIB.ORG

ABSTRACT Title of Dissertation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ABSTRACT Title of Dissertation ABSTRACT Title of dissertation: THE ASSOCIATION BETWEEN ELECTRONIC CIGARETTE USE AND CIGARETTE SMOKING BEHAVIOR AMONG YOUNG ADULTS IN THE UNITED STATES Blair N. Coleman, Doctor of Philosophy, 2015 Dissertation directed by: Associate Professor Kerry M. Green Department of Behavioral and Community Health The prevalence of electronic cigarette (e-cigarette) use is rapidly increasing in adults and youth; however, little is known about the public health impact of their use. A debate over e-cigarettes has emerged in the literature; one side recognizes the potential benefit of e-cigarettes as a harm reduction tool, while others argue e-cigarette use may delay or deter smoking cessation due to dual use or increase the risk of initiation of conventional cigarettes among previous nonsmokers. Drawing on the Theory of Planned Behavior, this dissertation focused on attitudes, beliefs, and perceived social norms of e- cigarettes, as well as openness to conventional cigarette smoking among young adult users of the product. Using a mixed methods approach, this dissertation analyzed secondary data from the 2012-2013 National Adult Tobacco Survey (NATS) as well as focus group data collected in five cities across the U.S. to better understand the relationship between e- cigarette use and cigarette smoking among young adults. In Study 1, quantitative analyses found non-cigarette smoking young adults who have tried e-cigarettes were more likely to report openness to cigarette smoking in the future compared to those who have not tried e-cigarettes (AOR= 2.4; 95% CI= 1.7-3.3). In Study 2, qualitative findings suggest that young adult exclusive e-cigarette users were less interested in conventional cigarette smoking, and overwhelmingly described negative aspects to cigarette smoking that appeared to become more salient as a result of their e-cigarette use. In Study 3, focus group participants expressed many positive attitudes towards e-cigarettes, and simultaneously reported a lack of information and knowledge about the products. The relationship between e-cigarette use and cigarette smoking is complex and multifaceted, and influenced by a myriad of individual and social factors. Although quantitative findings suggest young adults who have used e-cigarettes compared to those who have not used e-cigarettes were more likely to report openness to future cigarette smoking, qualitative findings did not support the notion that young adult e-cigarette users (who may have prior experience with cigarette smoking) are open to future cigarette smoking. These findings provide a basis for further exploration of the association between e-cigarette use and cigarette smoking. THE ASSOCIATION BETWEEN ELECTRONIC CIGARETTE USE AND CIGARETTE SMOKING BEHAVIOR AMONG YOUNG ADULTS IN THE UNITED STATES By Blair N. Coleman Dissertation submitted to the Faculty of the Graduate School of the University of Maryland, College Park in partial fulfillment of the requirements for the degree of Doctor of Philosophy 2015 Advisory Committee: Associate Professor Kerry M. Green, Chair Dr. Benjamin J. Apelberg Assistant Professor Craig S. Fryer Professor Dr. Sally A. Koblinsky Dr. Jessica M. Rath © Copyright by Blair N. Coleman 2015 Dedication This dissertation is dedicated first and foremost to the participants who shared their opinions and candid thoughts during the focus group study. Thank you for helping me understand your experiences, and by doing so, making this research possible. Also, to my grandmother, Dorothy Coleman, who inspired and encouraged me to pursue my dreams. ii Acknowledgements Throughout my doctoral program I have had incredible support from mentors, friends and family, and faculty members—a heartfelt thank you to each of you for helping me reach this accomplishment. To my dissertation committee Chair (and all-star mentor!), Dr. Kerry Green. Words cannot express how thankful I am to you for your guidance and encouragement throughout my doctoral program. From working as your TA, to quals preparations, and now to my dissertation you have always provided support and guidance in a way that challenged me and made me a better student. I have learned so much from you over the years—thank you. To Dr. Pamela Clark, for believing in me and giving me the incredible opportunity to work with the “dream team” during the first two years of my doctoral program. You have always challenged and inspired me to be a better writer, researcher, and person. Your support throughout my doctoral program has meant so much to me. Thank you. To Dr. Benjamin Apelberg, the opportunity you gave me to join your team at CTP back in 2012 was one of the best things to happen in my professional career. The ability to gain practical experience in tobacco regulatory science as a doctoral student shaped the type of public health professional I want to become. I continue to be inspired by your patience, passion, and dedication to public service. Thank you for guidance over the past three years, and for all of your support on this project. I am sincerely grateful to the rest of my dissertation committee for their time and support for this research—Dr. Jessica Rath, Dr. Sally Koblinsky, and Dr. Craig Fryer. The depth of knowledge and guidance each of you provided to this project was essential in helping me reach this stage. A special thank you to Dr. Jessica Rath, for your professional guidance and on-going support over the past several years. To my unbelievably talented and passionate colleagues at CTP—particularly Drs. Sarah Johnson and Bridget Ambrose—who have provided incredible support and guidance to me over the past three years. Working with you and sharing your passion created a situation where I enjoy coming to work every day. For that and for the incredible amount I have learned from you, thank you. Thank you to the faculty in the Department of Behavioral & Community Health who have guided me and provided unrelenting support—particularly Dr. Kathy Sharp and Dr. Robert Feldman. Also to my cohort—Erica, Alyssa, Krishna, Erin, Luciana, Daisy, Bina, and Tim—who have been incredibly supportive and caring since we started this journey together back in 2011. To the two mentors who made everything possible: Drs. Elbert Glover and Steven Pokorny. Dr. Glover, thank for your believing in me and giving me the incredible opportunity to complete my doctoral studies at the University of Maryland. I promised I would make you proud! Dr. Pokorny, over the years I have learned so much from you personally and professionally. I’m so grateful for the countless hours you have spent providing professional advice and guiding me every step of the way. You both have challenged me and encouraged me to accomplish things at times I thought were impossible. Thank you for always believing in me. iii Lastly, but certainly not least, to all of my friends and family—particularly my parents and Tom Nesmith—who have always encouraged and supported me, despite many moves across the country, work-filled weekends, and dare I say it—temper tantrums(!). Your love and support is what kept me going through the many years of undergraduate and graduate school, and is undoubtedly the main reason I was able to achieve this accomplishment—thank you. iv TABLE OF CONTENTS Dedication .................................................................................................................................... ii Acknowledgements ................................................................................................................... iii List of Figures and Tables ...................................................................................................... vii CHAPTER ONE: INTRODUCTION ................................................................................... 1 1.1 Background ..................................................................................................................................... 1 1.1.1 Regulation of E-Cigarettes ................................................................................................................ 3 1.1.2 Use of E-Cigarettes among Young Adults .................................................................................... 4 1.1.3 Debate over the Population Impact of E-Cigarettes ................................................................. 5 1.2 Conceptual Framework of the Study ........................................................................................ 6 1.3 Statement of the Problem ............................................................................................................. 9 1.4 Purpose of the Study .................................................................................................................. 10 1.5 Specific Aims, Hypotheses, and Research Questions ......................................................... 11 1.6 Summary ....................................................................................................................................... 12 1.7 Definition of Terms ..................................................................................................................... 13 CHAPTER TWO: LITERATURE REVIEW ................................................................... 16 2.1 Background on E-Cigarettes and Emergence in the U.S. Marketplace ......................... 16 2.1.1 Background and Diversity of E-Cigarette Products ............................................................... 16 2.1.2 Marketing and Sales of E-Cigarettes ..........................................................................................
Load more

Recommended publications
  • Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic Cheryl A
    University of Connecticut OpenCommons@UConn UCHC Articles - Research University of Connecticut Health Center Research 3-2011 Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic Cheryl A. Oncken University of Connecticut School of Medicine and Dentistry Follow this and additional works at: https://opencommons.uconn.edu/uchcres_articles Part of the Medicine and Health Sciences Commons Recommended Citation Oncken, Cheryl A., "Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic" (2011). UCHC Articles - Research. 243. https://opencommons.uconn.edu/uchcres_articles/243 NIH Public Access Author Manuscript Clin Pharmacol Ther. Author manuscript; available in PMC 2014 July 22. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Clin Pharmacol Ther. 2011 March ; 89(3): 392–399. doi:10.1038/clpt.2010.317. Immunogenicity and Smoking Cessation Outcomes for a Novel Nicotine Immunotherapeutic Dorothy K. Hatsukami1, Douglas E. Jorenby2, David Gonzales3, Nancy A. Rigotti4, Elbert D. Glover5, Cheryl A. Oncken6, Donald P. Tashkin7, Victor I. Reus8, Roxanne C. Akhavain9, Raafat E.F. Fahim9, Paul D. Kessler9, Minoo Niknian9, Matthew W. Kalnik9, and Stephen I. Rennard10 1Dept. of Psychiatry, University of Minnesota Tobacco Use Programs, Minneapolis, MN 2Department of Medicine, University of Wisconsin, Madison, WI 3Department of Medicine, Oregon Health & Sciences University, Portland, OR 4Tobacco Research and Treatment Center, Massachusetts
    [Show full text]
  • Antidepressants for Smoking Cessation (Review)
    Antidepressants for smoking cessation (Review) Hughes JR, Stead LF, Lancaster T This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2011, Issue 8 http://www.thecochranelibrary.com Antidepressants for smoking cessation (Review) Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 4 Figure1. ..................................... 9 Figure2. ..................................... 12 DISCUSSION ..................................... 15 AUTHORS’CONCLUSIONS . 16 ACKNOWLEDGEMENTS . 17 REFERENCES ..................................... 18 CHARACTERISTICSOFSTUDIES . 33 DATAANDANALYSES. 93 Analysis 1.1. Comparison 1 Bupropion. Abstinence at 6m or greater follow-up, Outcome 1 Bupropion versus placebo/control. Subgroups by length of follow-up. ............ 95 Analysis 1.2. Comparison 1 Bupropion. Abstinence at 6m or greater follow-up, Outcome 2 Bupropion versus placebo/control. Subgroups by clinical/recruitment setting. ................. 97 Analysis 1.3. Comparison 1 Bupropion. Abstinence at 6m or greater follow-up, Outcome 3 Bupropion versus placebo. Subgroups by level of behavioural support. .......... 100 Analysis
    [Show full text]
  • Smoking Cessation with Varenicline, a Selective
    ORIGINAL INVESTIGATION Smoking Cessation With Varenicline, a Selective ␣4␤2 Nicotinic Receptor Partial Agonist Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up Mitchell Nides, PhD; Cheryl Oncken, MD, MPH; David Gonzales, PhD; Stephen Rennard, MD; Eric J. Watsky, MD; Rich Anziano, MS; Karen R. Reeves, MD; for the Varenicline Study Group Background: Currently available smoking cessation cline tartrate, 1.0 mg twice daily (48.0%; PϽ.001) and 1.0 therapies have limited success rates. Varenicline tar- mg once daily (37.3%; PϽ.001), than for placebo (17.1%). trate is a novel, selective nicotinic receptor partial ago- The bupropion rate was 33.3% (P=.002 vs placebo). The car- nist developed specifically for smoking cessation. This bon monoxide–confirmed continuous quit rates from week study evaluated the efficacy, tolerability, and safety of 3 4 to week 52 were significantly higher in the varenicline tar- varenicline doses for smoking cessation. Bupropion hy- trate, 1.0 mg twice daily, group compared with the placebo drochloride was included as an active control. group(14.4%vs4.9%;P=.002).Thebupropionratewas6.3% (P=.60 vs placebo). Discontinuation owing to treatment- Methods: A phase 2, multicenter, randomized, double- emergent adverse events was 15.9% for bupropion, 11.2% blind, placebo-controlled study of healthy smokers (18-65 to14.3%forvarenicline,and9.8%forplacebo.Nodose-related years old). Subjects were randomized to varenicline tar- increases occurred in adverse events for varenicline. trate, 0.3 mg once daily (n=128), 1.0 mg once daily (n=128), or 1.0 mg twice daily (n=127), for 6 weeks plus Conclusions: Varenicline tartrate demonstrated both placebo for 1 week; to 150-mg sustained-release bupro- short-term (1 mg twice daily and 1 mg once daily) and pion hydrochloride twice daily (n=128) for 7 weeks; or long-term efficacy (1 mg twice daily) vs placebo.
    [Show full text]
  • Encyclopedia of Drug
    ADDICTIVE BEHAVIOR ENCYCLOPEDIA of DRUGS, ALCOHOL & ADDICTIVE BEHAVIOR Editorial Board EDITOR IN CHIEF Rosalyn Carson-DeWitt, M.D. Durham, North Carolina EDITORS Kathleen M. Carroll, Ph.D. Associate Professor of Psychiatry Yale University School of Medicine Jeffrey Fagan, Ph.D. Professor of Public Health Joseph L. Mailman School of Public Health, Columbia University Henry R. Kranzler, M.D. Professor of Psychiatry University of Connecticut School of Medicine Michael J. Kuhar, Ph.D. Georgia Research Alliance Eminent Scholar and Candler Professor Yerkes Regional Primate Center ADDICTIVE BEHAVIOR ENCYCLOPEDIA of DRUGS, ALCOHOL & ADDICTIVE BEHAVIOR SECOND EDITION VOLUME 3 R – Z ROSALYN CARSON-DEWITT, M.D. Editor in Chief Durham, North Carolina Copyright © 2001 by Macmillan Reference USA, an imprint of the Gale Group All rights reserved. No part of this book may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the Publisher. Macmillan Reference USA Macmillan Reference USA An imprint of the Gale Group An imprint of the Gale Group 1633 Broadway 27500 Drake Rd. New York, NY 10019 Farmington Hills, MI 48331-3535 Printed in the United States of America printing number 12345678910 Library of Congress Cataloging-in-Publication Data Encyclopedia of drugs, alcohol, and addictive behavior / Rosalyn Carson-DeWitt, editor-in-chief.–Rev. ed. p. cm. Rev. ed. of: Encyclopedia of drugs and alcohol. c1995. Includes bibliographical references and index. ISBN 0-02-865541-9 (set) ISBN 0-02-865542-7 (Vol. 1) ISBN 0-02-865543-5 (Vol.
    [Show full text]
  • Wake Forest Magazine December 2002
    2001-2002 Honor Roll of Donors Wake For e st M A G A Z I N E Volume 50, Number 2 December 2002 Editor: Cherin C. Poovey, poovey @wfu.edu Associate Editor: Kerry M. King (’85), [email protected] Senior Graphic Designer: Jessica Koman, [email protected] Graphic Designer: Sonya Peterson, [email protected] Photographer: Ken Bennett, [email protected] Class Notes Editor: Janet Williamson, [email protected] Contributing Writer: David Fyten, [email protected] Development Writer: Michael Strysick, [email protected] Printing: The Lane Press, Inc. Wake Forest Magazine (USPS 664-520 ISSN 0279-3946) is published four times a year in September, December, March and June by the Office of Creative Services, Wake Forest University, 1834 Wake Forest Road, Winston-Salem, NC 27109-7205. It is sent to alumni, donors and friends of the University. Periodicals postage paid at Winston-Salem, NC 27109, and additional mailing offices. Send letters to the editor ([email protected]), classnotes ([email protected]), change of address ([email protected]) and other correspondence to the e-mail addresses listed or to Wake Forest Magazine,P.O. Box 7205, Wake Forest University, Winston-Salem, NC 27109-7205. Telephone: (336) 758-5379. You can access the Web site at http://www.wfu.edu POSTMASTER: Send address changes to Wake Forest Magazine Alumni Records, P.O. Box 7227, Winston-Salem, NC 27109-7227. Volume 50, Number 2 Copyright 2002 Wake For e st M A G A Z I N E Features 12 Their Journey by Kerry M. King (’85) What lies ahead for eight freshmen? Follow them on their journey to 2006.
    [Show full text]
  • Smoking Cessation with Varenicline, a Selective 4 2 Nicotinic Receptor
    ORIGINAL INVESTIGATION Smoking Cessation With Varenicline, a Selective ␣4␤2 Nicotinic Receptor Partial Agonist Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up Mitchell Nides, PhD; Cheryl Oncken, MD, MPH; David Gonzales, PhD; Stephen Rennard, MD; Eric J. Watsky, MD; Rich Anziano, MS; Karen R. Reeves, MD; for the Varenicline Study Group Background: Currently available smoking cessation cline tartrate, 1.0 mg twice daily (48.0%; PϽ.001) and 1.0 therapies have limited success rates. Varenicline tar- mg once daily (37.3%; PϽ.001), than for placebo (17.1%). trate is a novel, selective nicotinic receptor partial ago- The bupropion rate was 33.3% (P=.002 vs placebo). The car- nist developed specifically for smoking cessation. This bon monoxide–confirmed continuous quit rates from week study evaluated the efficacy, tolerability, and safety of 3 4 to week 52 were significantly higher in the varenicline tar- varenicline doses for smoking cessation. Bupropion hy- trate, 1.0 mg twice daily, group compared with the placebo drochloride was included as an active control. group(14.4%vs4.9%;P=.002).Thebupropionratewas6.3% (P=.60 vs placebo). Discontinuation owing to treatment- Methods: A phase 2, multicenter, randomized, double- emergent adverse events was 15.9% for bupropion, 11.2% blind, placebo-controlled study of healthy smokers (18-65 to14.3%forvarenicline,and9.8%forplacebo.Nodose-related years old). Subjects were randomized to varenicline tar- increases occurred in adverse events for varenicline. trate, 0.3 mg once daily (n=128), 1.0 mg once daily (n=128), or 1.0 mg twice daily (n=127), for 6 weeks plus Conclusions: Varenicline tartrate demonstrated both placebo for 1 week; to 150-mg sustained-release bupro- short-term (1 mg twice daily and 1 mg once daily) and pion hydrochloride twice daily (n=128) for 7 weeks; or long-term efficacy (1 mg twice daily) vs placebo.
    [Show full text]